HIV Scientific Papers
Metabolic effects of tesamorelin (TH9507), a growth hormone-releasing factor analogue, in hiv-infected patients with excess abdominal fat. a pooled analysis of 2 multicenter, double-blind placebo-controlled phase 3 trials with 816 randomized patients [abs ...
2009
Falutz J, Mamputu J-C, Potvin D, et al.
The 18th Annual Canadian Conference on HIV/AIDS Research (CAHR); April 24-27, 2009; Vancouver, British Columbia, Canada.
Atherogenic lipid profile in treated HIV patients with increased visceral adiposity:association with more severe CVD risk parameters and response to tesamorelin (TH9507), a growth hormone-releasing factor (GRF) analogue.
2009
Falutz J, Mamputu J-C, Marsolais C, et al.
Poster #713 presented at: Conference on Retroviruses and Opportunistic Infections; February 8-11, 2009; Montréal, Québec, Canada.
Metabolic effects of tesamorelin, a growth hormone-releasing hormone analogue, in HIV-infected patients with excess abdominal fat: a pooled analysis of 2 multicenter, randomized, placebo-controlled phase 3 trials [abstract].
2009
Falutz J, Mamputu J-C, Potvin D, et al.
EACS - 12th European AIDS Conference; November 11-14, 2009; Cologne, Germany.
Metabolic effects of tesamorelin, a growth hormone-releasing hormone analogue, in HIV-infected patients with excess abdominal fat: a pooled analysis of 2 multicenter, randomized, placebo-controlled phase 3 trials.
2009
Falutz J, Mamputu J-C, Potvin D, et al.
Poster #BPD2/1 presented at: EACS - 12th European AIDS Conference; November 11-14, 2009; Cologne, Germany.
Results from the 26-week confirmatory, phase 3 trial of tesamorelin (TH9507), a growth hormone-releasing factor analogue, in HIV patients with excess abdominal fat: a multicenter, double-blind, placebo- controlled study with 404 randomized patients.
2008
Falutz J, Marsolais C, Allas S, et al.
Poster #LBPE1156 presented at: XVII International AIDS Conference; August 3-8, 2008; Mexico City, Mexico.